102-11-4

Usage

Uses

Used in Chemical Synthesis:
NB-DMEA is used as a reagent in various chemical synthesis processes for its ability to facilitate reactions and improve the yield of desired products. Its high boiling points and solubility in water make it a preferred choice in the synthesis of complex organic compounds.
Used in Laboratory Research:
NB-DMEA is used as a research chemical in laboratories for conducting experiments and studying its properties and potential applications. Its clear liquid form and functional properties make it suitable for a wide range of laboratory applications, including the development of new chemical processes and the investigation of its interactions with other compounds.
Used in Pharmaceutical Industry:
NB-DMEA is used as an intermediate in the synthesis of pharmaceutical compounds, particularly in the development of new drugs. Its unique chemical structure and properties make it a valuable component in the creation of novel therapeutic agents, contributing to the advancement of medicine and healthcare.
Used in Environmental Protection:
NB-DMEA is used in the development of environmentally friendly processes and products, such as green chemistry and sustainable manufacturing. Its properties can be harnessed to reduce the environmental impact of chemical processes, promote waste reduction, and support the development of eco-friendly technologies.

InChI:InChI=1/C11H18N2/c1-12-8-9-13(2)10-11-6-4-3-5-7-11/h3-7,12H,8-10H2,1-2H3

Upstream product

• 23510-18-1 2-(N-benzyl-N-methylamino)ethyl chloride hydrochloride 
• 74-89-5 methylamine 
• 61372-53-0 1,3-Dimethyl-2-phenyl-imidazolinium iodid 
• 17542-47-1 benzyl-(2-chloro-ethyl)-methyl-amine 
• 100-44-7 benzyl chloride 
• 110-70-3 N,N`-dimethylethylenediamine 
• 23229-37-0 1,3-dimethyl-2-phenylimidazolidine 
• 104-88-1 4-chlorobenzaldehyde 
• 23281-56-3 1,3-dimethyl-2-(4-chlorophenyl)imidazolidine 
• 103-67-3 benzyl-methyl-amine 
• 179874-14-7 tert-butyl (2-(benzyl(methyl)amino)-2-oxoethyl)carbamate 

Downstream Products

• 735226-77-4 Furan-2-carboxylic acid [2-(benzyl-methyl-amino)-ethyl]-methyl-amide 
• 98902-01-3 N-[2-(Benzyl-methyl-amino)-ethyl]-N-methyl-benzamide 
• 870449-82-4 3,4,5-trimethoxybenzoic acid 3-[[2-(benzylmethylamino)ethyl]methylamino]propyl ester 
• 785751-76-0 N-Benzyl-N'-{3-[2-(4-fluoro-phenyl)-[1,3]dioxolan-2-yl]-propyl}-N,N'-dimethyl-ethane-1,2-diamine 

Relevant academic research and scientific papers

Chiral ureas and thioureas supported on polystyrene for enantioselective aza-Henry reactions under solvent-free conditions

Novel bifunctional ureas and thioureas immobilized on sulfonylpolystyrene have been prepared as recoverable and reusable organocatalysts and have been used in the stereoselective aza-Henry reaction under solvent-free conditions. The activity and stereoselection of the catalysts are dependent on the length of the tether bridging the active site and the polymer, the catalyst derived from 1,6-hexane diamine being the best one. It has also been demonstrated that the supported catalysts are more effective than the homologous soluble catalysts.

Reductive lithiation of 1,3-dimethyl-2-arylimidazolidines

Naphthalene catalyzed lithiation of 1,3-dimethyl-2-phenylimidazolidine led to cleavage of the benzylic carbon-nitrogen bond, with formation of an intermediate dianion. Under similar conditions, 1,3-dimethyl-2-(4-chlorophenyl) imidazolidine underwent regioselective cleavage of the aromatic carbon-chlorine bond, leading to a 4-formylphenyllithium equivalent, whilst 1,3-dimethyl-2-(4- methoxymethylphenyl)imidazolidine underwent regioselective cleavage of the benzylic carbon-oxygen bond, leading to a 4-formylbenzyllithium equivalent.

7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics

Compound 1 (1-benzyl-3-methyl-4-[4-(4-fluorophenyl)-4- oxobutyl]piperazine), a synthetic intermediate identified as a potential atypical antipsychotic, was selected as the starting point for pharmacological improvement. From 1, sequential structural variations were conducted in order to improve its potency and oral bioavailability. These variations included a series of piperazine, ethanediamine, and piperidine derivatives. The piperidine series afforded some orally potent compounds in the inhibition of apomorphine-induced climbing and hyperactivity in mice, which are regarded as behavioral models predictive of antipsychotic efficacy. Further optimization of these structures led to the highly potent 7-[3-(1- piperidinyl)propoxy]chromenones. Inhibition of stereotypies and induction of catalepsy in rats at doses substantially higher than required for inhibition of climbing suggest an atypical antipsychotic profile, which is assumed to predict a reduced induction of extrapyramidal side effects in humans.

Reduction of Substituted 1H-4,5-Dihydroimidazolium Salts

Reactions of several substituted 1H-4,5-dihydroimidazolium salts 1 with nucleophilic and electrophilic reducing agents acting via hydride transfer were explored.Reaction of compounds 1 with lithium aluminum hydride in THF afforded the corresponding imidazolidines 2.When alkaline borohydrides (sodium borohydride, potassium borohydride, sodium cyanoborohydride) in ethanol at room temperature were used, partial or total over-reduction of compounds 2 leading to N,N,N'-trisubstituted ethylenediamines took place on occasion.Results may be explained taking into account that reductive cleavage of 2 proceeds via a stabilized iminium ion present in protic solvents.Treatment of compounds 1 with an excess of borane in THF afforded the corresponding imidazolidines 2 or their borane complexes, according to the substituent type.

Synthesis and antihypertensive activity of a series of 4-amino-6,7-dimethoxyquinazoline derivatives

A series of N2-[(acylamino)alkyl]-6,7-dimethoxy-2,4-quinazolinediamines was synthesized as potential α1-adrenoceptor antagonists. When administered to spontaneously hypertensive rats at 10 mg/kg po, a number of propanediamine derivatives showed good antihypertensive activity, whereas the ethanediamine derivatives, albeit being structurally more closely related to prazosin, were devoid of this property. The most active derivative, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- 2-furancarboxamide hydrochloride, alfuzosin, showed high selectivity for peripheral α1-postjunctional adrenoceptors. At equiactive antihypertensive doses, its effect on the pressor response to postural changes in conscious dog was less marked than that shown by prazosin. In the light of these results, alfuzosin was selected for clinical evaluation.